Related Experiment Video
Updated: Mar 13, 2026

11:15
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
8.5K
Human cytomegalovirus-based immunotherapy to treat glioblastoma: Into the future
Sanne Duinkerken1, Yvette van Kooyk1, Juan J Garcia-Vallejo1
1Department of Molecular Cell Biology and Immunology, VUmc , Amsterdam, the Netherlands.
Oncoimmunology
|October 21, 2016
Abstract:
Glioblastoma multiforme (GBM) is the most aggressive brain tumor and median survival time with current therapies is only 14.6 mo. Although multiple immunotherapeutic strategies are being explored, efficacy remains poor. In order to improve immunotherapy for GBM, we propose to combine currently used endogenous with human cytomegalovirus (HCMV) specific antigens expressed on cancer cells.

